NCT00415129View on ClinicalTrials.gov

Safety and Immunogenicity of an Intramuscular Pandemic Influenza Vaccine in Adults and the Elderly

PHASE2CompletedINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

December 31, 2008

Study Completion Date

March 31, 2009

Conditions
InfluenzaOrthomyxoviridae Infections
Interventions
BIOLOGICAL

A/H5N1 inactivated, split-virion influenza virus

0.5mL, Intramuscular

BIOLOGICAL

A/H5N1 inactivated, split-virion influenza virus

0.5mL, Intramuscular

Trial Locations (4)

Unknown

Ghent

Leuven

Wilrijk

Oxford

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT00415129 - Safety and Immunogenicity of an Intramuscular Pandemic Influenza Vaccine in Adults and the Elderly | Biotech Hunter | Biotech Hunter